Prof. Dr. med. Adam Czaplinski is an FMH-certified neurologist and highly respected multiple sclerosis specialist. His specializations also include neuromuscular diseases and polyneuropathies.
Prof. Dr. med. Adam Czaplinski completed his neurologist training primarily in the Department of Neurology at University Hospital Basel (Prof. Andreas Steck and Prof. Ludwig Kappos), where he spent several years working as a senior physician. Most recently he was the acting chair of the Neurology and Neurosurgery Outpatient-Clinic. Prof. Czaplinski completed his further training in the United States in the Department of Neurology at Baylor College of Medicine and at the Methodist Neurological Institute (Prof. Stanley Appel) in Houston, Texas, prior to completing his postdoctoral tertiary teaching qualification (venia legendi) upon returning to the University of Basel.
In addition to his work as a clinician in Zurich, Aarau and Basel, he is an associate doctor in the Department of Neurology at University Hospital Basel. He is also an affiliated and consulting physician at multiple Hirslanden Klinik locations (Klinik Hirslanden Zurich, Hirslanden Klinik im Park Zurich, Hirslanden Klinik Aarau, Andreasklinik Cham). Professor Czaplinski has authored a number of scientific publications and is a member of Swiss, European and American Neurological Associations.
Professional experience
- 2009 – present
- Chair of NeuroCentre Bellevue in Zurich. Clinician at NeuroCentre Enge Zurich, NeuroCentre Basel and NeuroCentre Aarau. Affiliated doctor at multiple Hirslanden Klinik locations (Klinik Hirslanden Zürich, Hirslanden Klinik Im Park Zürich, Hirslanden Klinik in Aarau, Andreasklinik in Cham)
- 2008 – 2009
- Acting chair of Neurology and Neurosurgery Outpatient Clinic
- 2002 – 2008
- Senior physician, Department of Neurology, University of Basel
- 2003 – 2005
- Postdoctoral fellow in the Department of Neurology, Baylor College of Medicine and Methodist Neurological Institute, Houston, Texas, USA
- 1999 – 2002
- Assistant physician, Department of Neurology, University of Basel
- 1998 – 1999
- Assistant physician, Neurosurgery Clinic, Kantonsspital Aarau
- 1997 – 1998
- Assistant physician, Neurology/Neurorehabilitation, Rehaklinik Rheinfelden
- 1995 – 1997
- Assistant physician, Neurology/Internal Medicine, Swiss Paraplegic Center, Basel
- 1994 – 1995
- Assistant physician, Internal Medicine, Kantonsspital Bruderholz
Education and degrees
- 2010 – 2018
- Member of the scientific advisory board of the Swiss Multiple Sclerosis Society
- 2008 – 2011
- Vice President of the Swiss Muscle Society
- 2007
- Postdoctoral tertiary teaching qualification, venia legendi, University of Basel
- 2003
- SGKN certificate of competence in electroencephalography (EEG)
- 2003
- SGKN certificate of competence electroneurography and electromyography (ENMG)
- 2002
- FMH-certified neurology specialist
- 2001
- Dissertation: “Predictive value of T2-lesion volume for the natural course of multiple sclerosis.” University of Basel, Prof. Dr. Ludwig Kappos
- 1987 – 1994
- Studies in human medicine at Medical University of Gdansk, Poland and University of Basel, Switzerland Distinctions
Awards
- Recipient of the Sheila Essey Fellowship Award for ALS Research
- Fellow of the Swiss National Science Foundation
- Fellow of the Fonds zur Förderung des Akademischen Nachwuchses der Universität Basel
- Fellow of the Houston Endowment
Memberships
- Swiss Neurological Society (SNG)
- Swiss Society for Clinical Neurophysiology (SGKN)
- European Neurological Society (ENS)
- American Academy of Neurology (AAN)
- Polish Neurological Society (PTN)
- Swiss Muscle Society (SGMK)
- Swiss Muscular Dystrophy Association (SGMK)
- Swiss Medical Association (FMH)
Languages
- German
- English
- Polish
- Russian
Publications and lectures
Prof. Adam Czaplinski is a regular speaker at neurological conferences in Europe and in the USA and the author of numerous publications.
Ocrelizumab in Switzerland – first experiences
Swiss Federation of Clinical Neurosocieties SFCNS, September 2017
Interlaken/Switzerland
TGA: an altitude sickness?
European Academy of Neurology, June 2017
Amsterdam/Netherlands
Real-life long-term effectiveness of fingolimod in a Swiss relapsing-remitting multiple sclerosis cohort
American Academy of Neurology, April 2017
Boston/USA
Final results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with RR-MS (SWISSASCENT)
ECTRIMS, September 2016
London/UK
Role of Family Planning in Women of Child-Bearing Age with Multiple Sclerosis (MS) in Switzerland: Results of the Women with MS (WWMS) Patient Survey
American Academy of Neurology April 2016
Vancouver/Canada
Alemtuzumab: real life experience in Switzerland
Swiss Federation of Clinical Neurosocieties SFCNS, November 2015
Bern/Switzerland
Fingolimod treatment induces changes in NK and T helper cell subpopulations and in T cell co-stimulation markers.
ECTRIMS, October 2015
Barcelona/Spain
Stem cells for Amyotrophic Lateral Sclerosis.
European Academy of Neurology Meeting, June 2015
Berlin/Germany
Adherence and compliance in MS therapy.
Polish Neurological Society, March 2015
Lodz/Poland
Alemtuzumab: restoring the immune system.
Swiss Neurological Society, October 2014
Interlaken/Switzerland
Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
German Neurological Society, September 2014
Munich/Germany
Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis.
ECTRIMS/ACTRIMS Congress, September 2014
Boston/USA
Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT).
European Neurological Society Congress, June 2014
Istanbul/Turkey
Prolonged-release fampridine in multiple sclerosis: improved ambulatory function by subject-specific changes of the walking pattern.
American Academy of Neurology Congress, Mai 2014
Philadelphia/USA
Swiss post marketing surveillance monitoring quality of life and treatment.
Journées de Neurologie de Langue Française, April 2014
Strasbourg/France
Interim results of the Swiss post marketing surveillance monitoring quality of life and treatment satisfaction in patients with relapsing-remitting multiple sclerosis (SWISSASCENT)
ECTRIMS Congress, October 2013
Copenhagen/Denmark
“Therapie der Multiplen Sklerose: vom Cortison zur differenzierten Immunomodulation.”
13th Swiss-Russian General Practitioners Conference, May 2013
St. Petersburg/Russia
“Tysabri in der Behandlung der Multiplen Sklerose”
MS State of The Art 2013, March 2013
Lodz/Poland
Novel electrochemiluminescence based immunoassay: neurofilament light chain in serum as a marker of axonal damage
William Harvey Day, Queen Mary University, October 2012
London/United Kingdom
A Swiss best practice experience in three different clinical settings of the 6 hour fingolimod observation procedure.
ECTRIMS Congress, October 2012
Lyon/France
Utilization of JC-Virus antibody testing in clinical practice.
ECTRIMS Congress, October 2012
Lyon/France
Tysabri: new data to efficacy and safety.
Central European Tysabri Advisory Board (CETAB) Meeting, October 2012
Vienna/Austria
Fingolimod in daily practice.
Swiss Neurological Society (SNG) Meeting, Mai 2012
Lugano/Switzerland
Update on current treatment strategies in MS
American Academy of Neurology (AAN) Meeting, participant, April 2012
New Orleans/USA
Tysabri: efficacy and safety update.
Central European Tysabri Advisory Board (CETAB) Meeting, January 2012
Bratislava/Slovakia
Personalized treatment strategies in Multiple Sclerosis.
ECTRIMS Congress, October 2011
Amsterdam/Netherlands
Treatment failure: what to do?
MS State of the Art, January 2011
Lucerne/Switzerland
MS therapy update.
ECTRIMS Congress, October 2010
Göteborg/Sweden
Current therapeutic strategies in MS.
European Neurological Society Congress (participant), June 2010
Berlin/Germany
Oral laquinimod for Multiple Sclerosis.
TEVA Symposium, Mai 2010
Jerusalem/Israel
The effect of IFNbeta 1b treatment on cognition in Multiple Sclerosis.
Advisory Board meeting, March 2010
Rome/Italy
Treatment failure, what to do?
Multiple Sclerosis State of the Art, Januar 2010
Luzern/Switzerland
Safety overview of fingolimod.
Fingolimod Advisory Board, December 2009
Berlin/Germany
New oral agents in the therapy of Multiple Sclerosis.
Cladribine Advisory Board, November 2009
Amsterdam/Netherlands
“Phasenadaptierte Therapie der Multiplen Sklerose.”
182nd conference of the Swiss Neurological Society, June 2009
Interlaken/Switzerland
Application of the Database Controls in Experimental Trials.
Annual Meeting of St.Lukes Hospital, April 2009
Tokyo/Japan
“ALS: Can We Predict the Course of Disease?”
19th congress of the Scientific Advisory Board of the DGM, March 2009
Darmstadt/Germany
Natalizumab in daily practice- risks and benefits.
11th State of the Art Symposium, January 2009
Berne/Switzerland
“Strategien zur Optimierung der immunomudulatorischen Therapie der MS.”
Zurich MS roundtable, October 2008
Zurich/Switzerland
“Moderne Therapie der Multiplen Sklerose”
Quadrimed Kongress, May 2008
Crans Montana/Switzerland
Reconsidering clinical outcomes: relapses, impairment, disability and beyond.
Symposium of the European Charcot Foundation, November 2007
Fiuggi/Italy
Length of prediagnostic period as a predictor of rate of disease progression and survival in ALS.
17th Meeting of the European Neurological Societ, June 2007
Rhodes/Greece
“Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?”
177th conference of the Swiss Neurological Society, October 2006
Interlaken/Switzerland
Amyotrophic Lateral Sclerosis: Can We Predict the Course of Disease?
Kongress der Polnischen Neurologischen Gesellschaft, September 2006
Krakow/Poland
Predictability of disease progression in amyotrophic lateral sclerosis.
XVIth Meeting of the European Neurological Society, Mai 2006
Lausanne/Switzerland
Slower disease progression and prolonged survival in contemporary ALS patients: is the natural history of ALS changing?
58th Annual Meeting of American Academy of Neurology, April 2006
San Diego/USA
Predictability of disease progression in amyotrophic lateral sclerosis.
16th International Symposium on ALS/MND, December 2005
Dublin/Ireland
Amyotrophic lateral sclerosis: early predictors of prolonged survival.
World Congress of Neurology, November 2005
Sydney/Australia
Application of the Database Controls in Experimental Trials for Amyotrophic Lateral Sclerosis.
57th Annual Meeting of American Academy of Neurology, April 2005
Miami/USA
Flail arm syndrome: a clinical variant of amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey
Pathological crying as the initial presenting symptom in amyotrophic lateral sclerosis.
XIIIth Meeting of the European Neurological Society, June 2003
Istanbul/Turkey
Symptomatic care in ALS
Basler ALS Symposium, March 2003
Basel/Switzerland
Predictive value of T2-lesion volume for the natural course of multiple sclerosis.
Meeting of the Polish Neurological Society, September 200
Poznan/Poland
Rapid progressive, sensory-motor demyelinating neuropathy.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada
Ice pack test for myasthenia gravis: a simple, noninvasive and safe diagnostic method.
Xth International Neuromuscular Congress, July 2002
Vancouver/Canada
The natural course of multiple sclerosis: predictive value of lesion volume in T2-weighted brain MRI.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany
Necrotising vasculitis and isotretinoin.
XIIth Meeting of the European Neurological Society, June 2002
Berlin/Germany